Gene and cell therapies offer the potential to transform the treatment pathway for patients with some of the most debilitating conditions. However, with costs routinely exceeding $1 million per treatment, these therapies can create a significant financial burden for employers.

As benefit costs continue to escalate, many employers are searching for ways to gain more control over their expenses. One solution they may consider is using an alternative funding arrangement for their employee benefits.